Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned an average recommendation of “Hold” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $13.1429.

JSPR has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Tuesday, April 21st. Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. TD Cowen downgraded shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, UBS Group initiated coverage on shares of Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating for the company.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $0.90 on Friday. Jasper Therapeutics has a 52-week low of $0.62 and a 52-week high of $7.19. The company has a market capitalization of $25.28 million, a P/E ratio of -0.28 and a beta of 3.07. The company has a 50-day simple moving average of $0.96 and a 200 day simple moving average of $1.38.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. As a group, equities analysts forecast that Jasper Therapeutics will post -1.81 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently bought and sold shares of JSPR. Propel Bio Management LLC bought a new position in Jasper Therapeutics in the 3rd quarter valued at about $2,449,000. Kingdon Capital Management L.L.C. raised its holdings in Jasper Therapeutics by 93.5% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock valued at $3,153,000 after acquiring an additional 640,138 shares during the period. Knott David M Jr bought a new position in Jasper Therapeutics in the 3rd quarter valued at about $408,000. Readystate Asset Management LP bought a new position in Jasper Therapeutics in the 3rd quarter valued at about $234,000. Finally, Jain Global LLC bought a new position in Jasper Therapeutics in the 4th quarter valued at about $79,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.